Improved HbA1c and body weight in GADA-positive individuals treated with tirzepatide: A post hoc analysis of SURPASS.

Anne L PetersRaffaella BuzzettiA Richey SharrettImre PavoMinzhi LiuChrisanthi A KaranikasJim S Paik

Published in: The Journal of clinical endocrinology and metabolism (2024)

In this post hoc analysis, tirzepatide was associated with substantial reductions in HbA1c and BW irrespective of GADA status in adults diagnosed with T2D, suggesting that tirzepatide may improve glycemic control in individuals with LADA.

Keyphrases

body weight
glycemic control
type diabetes
blood glucose
weight loss
insulin resistance
adipose tissue